Langley J, Vergne-Marini P, Dickerman R M, Brinker K R, Land G
Methodist Medical Center Transplant Program, Dallas, Texas 75208.
Transplant Proc. 1991 Apr;23(2):1757-9.
The incidence of DRF in the regraft study group was most commonly seen in patients with a historic high level of HLA sensitization. Primary NF was an immune mediated event seen in 63% of third regrafts. Delayed use of CyA with ALG induction coverage provides good graft survival with either double or triple maintenance therapy. Stricter patient selection for third transplants and aggressive clinical monitoring of the regrafted patient has provided a 1-year actuarial graft survival result of 88% at our transplant center.
再移植研究组中DRF的发生率最常见于既往HLA致敏水平较高的患者。原发性NF是一种免疫介导事件,在63%的第三次再移植中可见。在使用ALG诱导覆盖的情况下延迟使用环孢素(CyA),无论是双重还是三重维持治疗,均能提供良好的移植物存活率。对第三次移植进行更严格的患者选择以及对再移植患者进行积极的临床监测,使得我们移植中心1年的精算移植物存活率达到了88%。